Publications by authors named "Olov Wiklund"

Claim this Profile
[
[Elderly benefit from lower LDL-cholesterol].
Olov Wiklund

Lakartidningen· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning.
Ana Pina, Saga Helgadottir, Rosellina Margherita Mancina, Chiara Pavanello, Carlo Pirazzi, Olov Wiklund

Eur J Prev Cardiol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.
Jan Borén, M John Chapman, Ronald M Krauss, Chris J Packard, Jacob F Bentzon, Olov Wiklund

Eur Heart J· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM.
Michel R Langlois, Børge G Nordestgaard, Anne Langsted, M John Chapman, Kristin M Aakre, Olov Wiklund

Clin Chem Lab Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.
Børge G Nordestgaard, Michel R Langlois, Anne Langsted, M John Chapman, Kristin M Aakre, Olov Wiklund

Atherosclerosis· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Olov Wiklund

Eur Heart J· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the Patient Perception of Statin Experience: A Qualitative Study.
Michal Vrablik, Alberico L Catapano, Olov Wiklund, Yi Qian, Pratik Rane

Adv Ther· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High prevalence of genetic determined familial hypercholesterolemia in premature coronary artery disease.
Carlo Pirazzi, Lina Håkansson, Carola Gustafsson, Elmir Omerovic, Olov Wiklund

Appl Clin Genet· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New prospects for PCSK9 inhibition?
Ulf Landmesser, M John Chapman, Jane K Stock, Pierre Amarenco, Jill J F Belch, Olov Wiklund

Eur Heart J· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.
François Mach, Kausik K Ray, Olov Wiklund, Alberto Corsini, Alberico L Catapano

Eur Heart J· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.
Michel R Langlois, M John Chapman, Christa Cobbaert, Samia Mora, Alan T Remaley, Olov Wiklund

Clin Chem· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.
Ulf Landmesser, M John Chapman, Jane K Stock, Pierre Amarenco, Jill J F Belch, Olov Wiklund

Eur Heart J· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.
Ian Graham, Chuck Shear, Pieter De Graeff, Caroline Boulton, Alberico L Catapano, Olov Wiklund

Eur Heart J Cardiovasc Pharmacother· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia.
Piero Pingitore, Saverio Massimo Lepore, Carlo Pirazzi, Rosellina Margherita Mancina, Benedetta Maria Motta, Olov Wiklund

J Clin Lipidol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.
Ulf Landmesser, M. John Chapman, Michel Farnier, Baris Gencer, Stephan Gielen, Olov Wiklund

Eur Heart J· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Olov Wiklund

Eur Heart J· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias].
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman

Kardiol Pol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[PCSK9 inhibitors reduces LDL cholesterol by 60 percent].
Peter Nilsson, Olov Wiklund

Lakartidningen· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman

Rev Esp Cardiol (Engl Ed)· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis.
Piero Pingitore, Paola Dongiovanni, Benedetta Maria Motta, Marica Meroni, Saverio Massimo Lepore, Olov Wiklund

Hum Mol Genet· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.
Björn W Karlson, Olov Wiklund, Michael K Palmer, Stephen J Nicholls, Pia Lundman

Eur Heart J Cardiovasc Pharmacother· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman

Eur Heart J· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

Atherosclerosis· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.
Børge G Nordestgaard, Anne Langsted, Samia Mora, Genovefa Kolovou, Hannsjörg Baum, Olov Wiklund

Clin Chem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Eur J Prev Cardiol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis